Premium
The value of progesterone receptor assays in the management of advanced breast cancer
Author(s) -
Degenshein George A.,
Bloom Norman,
Tobin Ellis
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801215)46:12+<2789::aid-cncr2820461409>3.0.co;2-k
Subject(s) - medicine , endocrine system , estrogen , estrogen receptor , progesterone receptor , breast cancer , receptor , ablative case , oncology , complete response , hormone , cancer , endocrinology , physiology , chemotherapy , radiation therapy
Estrogen and progesterone receptor determinations were performed on 518 specimens at the Surgical Research Laboratory of the Maimonides Medical Center. Of these, 41% were ERP and PgRP positive; 17% were ERP positive and PgRP negative; 38% were ERP negative and PgRP negative, and 3.9% were ERP negative, PgRP positive. Sixty‐two patients with advanced breast cancer were treated with either an endocrine ablative procedure or with antihormonal therapy. In the two treatment groups the overall response rate when both receptors were postive was 79%, with a higher percentage of responders in the endocrine ablative group (88% vs. 69%). In addition, a greater duration of response was achieved in those patients treated with endocrine ablation. The overall predictability of response or failure to hormonal therapy is 91% if the progesterone receptor alone is utilized to select treatment and an endocrine ablative procedure is performed. The predictability of response based on the estrogen receptors presence or absence is 70%.